Home › Funds › Parkman Healthcare Partners LLC › TARS
Parkman Healthcare Partners LLC position in TARS
TARSUS PHARMACEUTICALS INC · Health Care
Parkman Healthcare Partners LLC reported holding 213,395 shares of TARS (TARSUS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$16.8M, representing 1.51% of its reported portfolio and ranking #22 among its reported holdings. Parkman Healthcare Partners LLC has disclosed TARS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's TARS position evolved
Parkman Healthcare Partners LLC first disclosed a stake in TARS in Q2 2026 at 150,000 shares (US$9.4M). The position peaked in Q3 2026 at 213,395 shares, worth US$16.8M. Across 2 filings, Parkman Healthcare Partners LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 213,395 shares valued at US$16.8M — an increase of 63,395 shares quarter over quarter.. Notable position changes include a 42% increase in Q3 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 150.00K | $9.44M | New |
| Q3 2026 | 213.40K | $16.77M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TARS and 13F data
TARS (TARSUS PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in TARS — the largest reported positions include Deep Track Capital, LP (US$299.3M), RTW INVESTMENTS, LP (US$273.9M), Paradigm Biocapital Advisors LP (US$180.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TARS
- Deep Track Capital, LP 3.81M sh · $299.25M · Q3 2026
- RTW INVESTMENTS, LP 3.48M sh · $273.88M · Q3 2026
- Paradigm Biocapital Advisors LP 2.30M sh · $180.91M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.57M sh · $98.71M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 1.10M sh · $86.17M · Q3 2026
- Vestal Point Capital, LP 1.05M sh · $66.09M · Q2 2026
- Frazier Life Sciences Management, L.P. 728.64K sh · $45.86M · Q2 2026
- TCG Crossover Management, LLC 388.16K sh · $30.51M · Q3 2026
- Rock Springs Capital Management LP 285.12K sh · $22.41M · Q3 2026
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held TARS?
Parkman Healthcare Partners LLC has disclosed TARS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Parkman Healthcare Partners LLC's current position in TARS?
As of Q3 2026, Parkman Healthcare Partners LLC holds 213.40K shares of TARS (TARSUS PHARMACEUTICALS INC), valued at $16.77M, representing 1.51% of its reported portfolio and ranking #22.
Has Parkman Healthcare Partners LLC been buying or selling TARS?
In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC increased its position in TARS. The position peaked in Q3 2026 at 213.40K shares.
Which other funds hold TARS?
Other major institutional holders of TARS include Deep Track Capital, LP, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.